| Company Name: |
SPIRO PHARMA |
| Tel: |
|
| Email: |
eric_feng1954@126.com |
NNC 61-0029 manufacturers
- Ragaglitazar
-
- $639.00
-
2026-07-27
- CAS:222834-30-2
- Purity: 98.56%
- Supply Ability: 10g
|
| | NNC 61-0029 Basic information |
| Product Name: | NNC 61-0029 | | Synonyms: | NNC 61-0029;WMUIIGVAWPWQAW-DEOSSOPVSA-N;Benzenepropanoic acid, α-ethoxy-4-[2-(10H-phenoxazin-10-yl)ethoxy]-, (αS)-;(-)-DRF-2725 | | CAS: | 222834-30-2 | | MF: | C25H25NO5 | | MW: | 419.48 | | EINECS: | | | Product Categories: | | | Mol File: | 222834-30-2.mol |  |
| | NNC 61-0029 Chemical Properties |
| Melting point | 89-90 °C | | Boiling point | 608.6±55.0 °C(Predicted) | | density | 1.241±0.06 g/cm3(Predicted) | | pka | 3.61±0.10(Predicted) |
| | NNC 61-0029 Usage And Synthesis |
| Uses | Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic. | | References | [1] Chakrabarti R, Vikramadithyan RK, Misra P, et al. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol. 2003;140(3):527-537. DOI:10.1038/sj.bjp.0705463
[2] Saad MF, Greco S, Osei K, et al. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care. 2004;27(6):1324-1329. DOI:10.2337/diacare.27.6.1324 |
| | NNC 61-0029 Preparation Products And Raw materials |
|